Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study

The excellent prognosis of patients with low-risk human papillomavirus (HPV)- associated oropharyngeal squamous cell carcinoma has led to concerns about overtreatment and excessive toxicity with radiation therapy and cisplatin, leading to interest in de-intensification trials. We investigated whether cetuximab, an epidermal growth factor receptor targeting antibody, when combined with radiation therapy would result in a decrease in symptom burden and toxicity with similar efficacy compared with weekly cisplatin.

Source: International Journal of Radiation Oncology * Biology * Physics - June 4, 2021 Category: Radiology Authors: Danny Rischin, Madeleine King, Lizbeth Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E. Jackson, Mathias Bressel, Alan Herschtal, Richard Fisher, Tsien Fua, Charles Lin, Chen Liu, Brett G.M. Hughes, Margaret McGrath, Lachlan McDowell, Tags: Clinical Investigation Source Type: research